FdaApplication
BLA 125469
Identifiers
- fda_app_no: BLA125469
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 2014-09-18 |
Revenue by product
TRULICITY
| Period | Revenue |
|---|---|
| Q2 2026 | $1.2B |
| Q1 2026 | $918.0M |
| Q4 2025 | $1.0B |
| Q3 2025 | $1.1B |
| Q2 2025 | $1.1B |
| Q1 2025 | $1.1B |
| Q4 2024 | $2.5B |
| Q3 2024 | $2.6B |
| Q2 2024 | $2.5B |
| Q1 2024 | $2.9B |
| Q4 2023 | $1.7B |
| Q3 2023 | $1.7B |
| Q2 2023 | $1.8B |
| Q1 2023 | $2.0B |
| Q4 2022 | $1.9B |
| Q3 2022 | $1.9B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
TRULICITY
| Period | Revenue |
|---|---|
| Q2 2026 | $1.2B |
| Q1 2026 | $918.0M |
| Q4 2025 | $1.0B |
| Q3 2025 | $1.1B |
| Q2 2025 | $1.1B |
| Q1 2025 | $1.1B |
| Q4 2024 | $2.5B |
| Q3 2024 | $2.6B |
| Q2 2024 | $2.5B |
| Q1 2024 | $2.9B |
| Q4 2023 | $1.7B |
| Q3 2023 | $1.7B |
| Q2 2023 | $1.8B |
| Q1 2023 | $2.0B |
| Q4 2022 | $1.9B |
| Q3 2022 | $1.9B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TRULICITY | DULAGLUTIDE | 1.5MG/0.5ML | Injection |
| TRULICITY | DULAGLUTIDE | 0.75MG/0.5ML | Injection |
| TRULICITY | DULAGLUTIDE | 1.5MG/0.5ML | Injection |
| TRULICITY | DULAGLUTIDE | 0.75MG/0.5ML | Injection |
| TRULICITY | — | 3MG/0.5ML | Injection |
| TRULICITY | — | 4.5MG/0.5ML | Injection |
6 products